John Lapré to fulfill role as Elekta’s Chief Technology Officer

STOCKHOLM, April 20, 2016 – In order to further strengthen its innovation
leadership, Elekta (EKTA-B.ST) announced today the appointment of John Lapré as
Chief Technology Officer, effective May 1, 2016.
John Lapré says: “The CTO responsibilities are to stimulate growth through
innovation and to further raise customer satisfaction with the clinical
effectiveness of Elekta’s portfolio.”

Tomas Puusepp, President and CEO, says the role demonstrates the company’s
continued commitment to advancing health care and improving outcomes for
patients. He says: “John Lapré will be an ideal CTO. In addition to intimately
knowing the company and our industry, he has a keen understanding of
collaboration and innovation, which are key elements for our customers and their
patients.”

John Lapré previously held the title of Executive Vice President Research and
Innovation at Elekta. Prior to this, he was Executive Vice President
Brachytherapy and before joining Elekta in 2011, John was Vice President R&D at
Nucletron.

John Lapré received his MSc and PhD in Toxicology & Nutrition in the
Netherlands, majoring in intestinal physiology, toxicology and biochemistry. His
PhD focused on the prevention of colorectal cancer.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on April 20, 2016.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.